Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa

Oskardmay, Ashley N; Miles, J. Alex; Sayed, Christopher

doi:10.1016/j.jaad.2019.05.022

Cited by 42 publications

(34 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since then, a dose of 10 mg/kg every six to eight weeks has been proven to achieve significant improvement and was well tolerated by patients. Additionally, a regimen of 7.5–10 mg/kg every four weeks provided optimal mitigation of HS-related disease activity [ 56 , 57 ]. However, we do recommend therapeutic drug monitoring before administering these intensified regimens.…”

Section: Implementation Of Biologics In Clinical Practicementioning

confidence: 99%

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

Aarts

Dudink

Vossen

et al. 2021

Drugs

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, recurrent, auto-inflammatory skin disease originating from the hair follicles. The typical inflammatory nodules, abscesses, and draining sinus tracts (tunnels) are characterized by a massive influx of neutrophils, macrophages, B-cells, plasma cells, T helper (Th)1, Th17 cells and upregulation of pro-inflammatory cytokines such as IL-1, IL-17, IL-12/23, and TNF-α. Over the last decades, several clinical trials evaluated the clinical efficacy of different biologics targeting these pro-inflammatory cytokines, in particular TNF-α and IL-1. However, adalimumab is still the only registered drug for HS. This review discusses biologics and small molecules with high level of evidence for their clinical application, provides guidance on when and how to use these biologics and small molecules in clinical practice, and elaborates on the combination with medical and surgical treatment options beyond the current guidelines. Furthermore this review provides an overview of potential biologics and small molecules currently under investigation for novel targets in HS such as IL-36, C5a, Janus kinase family members, CD-40, LTA4 and CXCR1/2.

show abstract

Section: Implementation Of Biologics In Clinical Practicementioning

confidence: 99%

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

Aarts

Dudink

Vossen

et al. 2021

Drugs

View full text Add to dashboard Cite

show abstract

“…A systematic review of 71 reported cases found ≥50% improvement in HS score in approximately 78% of patients [81]. A retrospective cohort study ( n = 52) concluded that the starting dosing schedule of 10 mg/kg every 6–8 weeks is more effective than lower starting doses [82]. Elevated interleukin (IL)-6 and high-sensitivity C-reactive protein may predict a better response to infliximab [83].…”

Section: Medical Management Of Hsmentioning

confidence: 99%

Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice

et al. 2020

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a chronic painful skin disease that severely impairs patients' quality of life. While high-quality trials of HS therapies remain limited, medical knowledge of best treatment practices is rapidly evolving, leading to the recent publication of multiple international treatment guidelines for HS. Summary: This review compares international HS treatment guidelines, describes evidence for effectiveness of common and emerging HS therapies, and provides guidance for integrating evidence-based HS care into practice. Although over 50 medical and procedural treatments are mentioned across international HS guidelines, only adalimumab and infliximab have grade B/ weak recommendation or higher across all major guidelines. This review describes the appropriate patient selection and effectiveness of the most commonly used medical and procedural treatments for HS. It also includes recommendations for counseling, dosing, and duration of medical therapies as well as procedure videos for the practicing dermatologist.

show abstract

“…[ 4 ]; Acitretin a second-generation oral retinoid which has descriptions of response to treatment of acute lesions doses of 0.25–0.88 mg/kg (3-12 months). Currently research is being carried out with inflammatory mediators such as inhibitors of different interleukins such as IL-1, IL-17, IL-12, IL-23, for which there are still studies that support or completely reject this practice; TNF inhibitors such as infliximab are also found with a recommended dose of 7.5 mg/kg every 4 weeks increasing the dose to 10 mg/kg every 4 weeks if necessary [ [37] , [38] , [39] ]. The Adalimumab dose of 80 mg for the first two weeks and subsequently 40 mg for 24 weeks, there was no increase in the number of abscesses and fistulas caused by HS [ 40 ].…”

Section: Pharmacological Managementmentioning

confidence: 99%

Hidradenitis suppurativa: Basic considerations for its approach: A narrative review

Anduquia-Garay

Rodríguez-Gutiérrez

Poveda-Castillo

et al. 2021

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Hidradenitis suppurativa is a chronic and debilitating skin disease, whose lesions can range from inflammatory nodules to abscesses and fistulas in the armpits, groin, perineum, inframammary region. Diagnosis can be confused with a large number of clinical pictures, and although studies on hidradenitis suppurativa are not so scarce in the literature, doctors are often unaware of this disease and therefore its diagnosis is often late. Pharmacological treatment ranges from retinoids to immunosuppression and radiation therapy, and surgical treatment ranges from incision and drainage to more complete excisions and laser therapies. Hidradenitis suppurativa is a disease seen and treated mainly by dermatologists and general surgeons, however, it is necessary for general practitioners to have basic knowledge about this entity, as they are the first line of care in the health system.

show abstract

Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa

Cited by 42 publications

References 15 publications

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice

Hidradenitis suppurativa: Basic considerations for its approach: A narrative review

Contact Info

Product

Resources

About